Navigation Links
Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
Date:11/11/2008

Study highlights:

- Researchers present promising results from dose-ranging study of new oral anti-coagulant in patients with acute coronary syndrome.

- Phase III trial slated to begin in December.

NEW ORLEANS, Nov. 11 /PRNewswire-USNewswire/ -- Researchers reported on a study of a new oral anti-clotting agent -- rivaroxaban -- designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

"The goal of any early study is to find the right dose and the right way to give the drug, and we met that objective," said C. Michael Gibson, M.S., M.D., principal investigator, chief of clinical research at the Beth Israel Deaconess Medical Center and director of the Thrombolysis in Myocardial Infarction (TIMI) data coordinating center at Brigham and Women's Hospital, Boston, Mass. "We studied four different doses and both once-a-day and twice-a-day dosing schedules for this Factor Xa, (pronounced ten-A) inhibitor."

The Phase II, randomized, placebo-controlled study on 3,491 patients treated at 297 medical centers in 27 countries originally had safety as the primary endpoint, but its design also included efficacy endpoints, he said. The primary efficacy endpoint was a composite of death, heart attack, stroke and severe ischemia revascularization. The secondary endpoint was a composite of death, heart attack or stroke.

Earlier studies had shown the experimental drug rivaroxaban effective at keeping blood clots from forming in the veins during and after major orthopedic surgery. ATLAS ACS-TIMI 46 is the first test of the drug in the arteries -- which face higher pressures than the venous circulation -- and the first study of the drug in acute coronary syndrome, defined as a heart attack or unstable angina, said Gibson.

The drug was added to t
'/>"/>

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
3. Derma Sciences Enrolls First Patient in DSC127 Phase II Study
4. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
5. Phase 2a Data for MEDI-528 Presented at CHEST 2008
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
8. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
9. Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
10. Teksouth Awarded $100,000 Defense Department Grant in First Phase of Medical Data Integration Project
11. Assessing the quality of phase I clinical trial abstracts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, August 18th ... of water for commercial and industrial properties. This was ... Archworks, LLC in Carmel, California. , This is a ... district in the State of California has approved this technology ... this time can now be used as a sole source ...
(Date:8/23/2014)... Athens, GA (PRWEB) August 23, 2014 Young adults ... drinking or doing drugs should pick up the phone and call ... troubled teen drug addict . , Troubled Teen Athens ... who is ready to finally take the necessary steps to end ... help, they are quick to go to friends or peers when ...
(Date:8/23/2014)... Wilmington, NC (PRWEB) August 23, 2014 ... across North Carolina. It’s no different in Wilmington, NC. ... Young adults are falling victim to drug and alcohol ... young people are looking to overcome substance abuse, but ... Finding an adolescent treatment facility can be a challenge ...
(Date:8/22/2014)... 23, 2014 Search Engine Optimization ... first page of search engines and get more ... has recently compared many Linux hosting suppliers and ... are the most recommended Linux hosting suppliers for ... Europe to buy high quality Linux hosting (including ...
(Date:8/22/2014)... On Friday, Aug. 22, Liberty University unveiled ... , hosting a ceremony in its courtyard attended by ... public welfare. , The 162-member inaugural class of the ... joined Liberty staff, faculty, and community leaders in celebrating ... medical school. Classes began on Monday, Aug. 4. , ...
Breaking Medicine News(10 mins):Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4
... Allscripts-Misys Healthcare,Solutions, Inc. (formerly named Allscripts Healthcare ... Delaware ("Allscripts") and,headquartered in Chicago, Illinois, announced today ... all of its 3.50% Convertible Senior Debentures,due 2024 ... 100% of the principal,amount of the Debentures being ...
... Watch and Jim Shank attribute the change to public outrage ... , WASHINGTON, Dec. 10 Wal-Mart Watch claimed ... a subrogation exception to the company,s 2009 health care plan ... Debbie Shank. , , ...
... ON. For the first time ever, an international ... the world,s tallest mountain, shedding some light on what ... on earth. , The team,s surprising findings shatter commonly-held ... falling ice and pulmonary oedema (lung problems) and highlight ...
... T ),has announced a contribution of A$38,000 ... support disadvantaged children in Australia. This is,the fifth ... Founded,in 1922, The Smith Family is a national, independent ... a better future,through education. , ...
... the United Kingdom and hires Michael Dyson to run European operations. ... ... -- DNA2.0, the leading gene synthesis and protein engineering company, today ... of the United Kingdom-based DNA2.0 Ltd. Michael Dyson, PhD, has been ...
... (duloxetine HCl) 60 mg to 120 mg once daily ... patients who had previously responded to the,medication and who ... patients who experienced at least three depressive episodes in ... Results from the 52-,week maintenance phase of the ...
Cached Medicine News:Health News:Allscripts Announces Expiration of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 2Health News:Wal-Mart's 2009 Health Care Plan Includes 'Debbie Shank Exception' 2Health News:Wal-Mart's 2009 Health Care Plan Includes 'Debbie Shank Exception' 3Health News:Team probes why climbers die on Mount Everest 2Health News:AT&T Supports the Smith Family's Learning For Life Program 2Health News:AT&T Supports the Smith Family's Learning For Life Program 3Health News:AT&T Supports the Smith Family's Learning For Life Program 4Health News:DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations 2Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 2Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 3Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 4Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 5Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 6
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)...   Zacks Equity Research highlights Epizyme (Nasdaq: EPZM ... Panera (Nasdaq: PNRA - Free Report ) as the Bear ... Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... - Free Report ). Here is a synopsis of ... : The biotech bull market is far from ...
(Date:8/22/2014)... Aug. 22, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, is pleased to ... medical cannabis conference taking place at the Faculty ... , on October 22, 2014.  The multilingual conference ... as researchers, health professionals, and patients, to discuss ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... Results Reported at American Association for Dental Research ... Parion Sciences, Inc., a,privately-held, development-stage pharmaceutical company dedicated ... body,s mucosal,defenses, today announced preliminary results from a ... channel blocker, P-552-02, as a topical,therapy for dry ...
... April 7 A biosimilar product for,treating the ... the,white blood cells of patients is safe and ... a reference,product. This is the result of a ... company Kwizda Pharma GmbH and the Indian manufacturer,INTAS ...
Cached Medicine Technology:Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 2Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 3Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 2Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 3
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
Rapid test for the presumptive identification of Candida albicans from culture media....
... is a system built ... and an imaging device ... zone size around an ... built-in expertise for detection ...
The best value and features offered in a complete EMR and Practice Management Solution...
Medicine Products: